AURX · Nuo Therapeutics, Inc.
$1.14
+0.04 (+3.64%)
At close · Aug 31
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We believe based on the operating cash requirements and capital expenditures expected for the next twelve months that our current resources and projected revenue from sales of Aurix products and the Private Label product to Smith+Nephew are insufficient to support our operations for the next 12 months from the date these financial statements are issued. As such, we believe that substantial doubt about our ability to continue as a going concern exists.”View the 10-Q filed Aug 14, 2026
Market Cap
$53.28M
Shares
48.43M
Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.
| Filed | Type | Industry | Offering | Sold | Exemptions |
|---|---|---|---|---|---|
| 2025-08-04 | New | Other Health Care | $791,418 | $791,418 | 06b |
| 2024-09-23 | New | Other Health Care | $849,125 | $849,125 | 06b |
| 2024-05-22 | New | Other Health Care | $650,875 | $650,875 | 06b |
| 2023-12-22 | New | Other Health Care | $962,500 | $962,500 | 06b |
| 2023-08-08 | New | Other Health Care | $1,035,000 | $1,035,000 | 06b |
| 2022-05-19 | New | Other Health Care | $407,757 | $407,757 | 06b |
| 2022-05-06 | New | Other Health Care | $3,550,000 | $3,550,000 | 06b |
Showing 1–7 of 7 filings